Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Asymptomatic transmission plays a prominent role in mpox infection patterns

15

May 2026

Asymptomatic transmission plays a prominent role in mpox infection patterns

A Kaiser Permanente study of nearly 8,000 men shows that in mid- to late 2024, mpox was far more common among men who have sex with men than previously thought. Individuals without symptoms accounted for most infections and likely played a prominent role in transmission, contrary to prior assumptions that people had to be symptomatic to spread the disease.

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

15

May 2026

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

Healthy plant-based foods may improve pregnancy cardiometabolic markers

15

May 2026

Healthy plant-based foods may improve pregnancy cardiometabolic markers

Higher-quality plant-based diets were associated with more favorable cardiometabolic biomarkers in pregnant U.S. women, especially higher HDL-C and lower TG/HDL-C ratio. Indices that emphasized healthy plant foods, rather than simply penalizing animal foods, showed the strongest links with insulin resistance and lipid markers.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.